New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
08:43 EDTAERIAerie Pharmaceuticals price target raised to $36 from $27 at RBC Capital
RBC Capital believes that Phase IIb results for Aerie's glaucoma treatment, Roclatan, lower the risks faced by the company. The firm says that the data would be good enough to support approval of the drug if the trial was a Phase III study. It keeps an Outperform rating on the shares.
News For AERI From The Last 14 Days
Check below for free stories on AERI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for AERI

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use